메뉴 건너뛰기




Volumn 12, Issue 1, 2014, Pages

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients

Author keywords

CHOP; DCK; hENT1; MRP1; Pancreatic ductal adenocarcinoma; RECPAM

Indexed keywords

DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; ANTINEOPLASTIC AGENT; DDIT3 PROTEIN, HUMAN; DEOXYCYTIDINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SLC29A1 PROTEIN, HUMAN;

EID: 84908121743     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0248-4     Document Type: Article
Times cited : (10)

References (35)
  • 4
    • 39749183343 scopus 로고    scopus 로고
    • Analysis of mortality rates for pancreatic cancer across the world
    • Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008, 10(1):58-62. 10.1080/13651820701883148.
    • (2008) HPB (Oxford) , vol.10 , Issue.1 , pp. 58-62
    • Hariharan, D.1    Saied, A.2    Kocher, H.M.3
  • 5
    • 0037103069 scopus 로고    scopus 로고
    • New applications of gemcitabine and future directions in the management of pancreatic cancer
    • 12209675
    • Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002, 95(4 Suppl):941-945. 10.1002/cncr.10753, 12209675.
    • (2002) Cancer , vol.95 , Issue.4 SUPPL , pp. 941-945
    • Abbruzzese, J.L.1
  • 6
    • 84864568987 scopus 로고    scopus 로고
    • Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
    • 22873289
    • Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J Transl Med 2012, 10:161. 10.1186/1479-5876-10-161, 22873289.
    • (2012) J Transl Med , vol.10 , pp. 161
    • Rathos, M.J.1    Joshi, K.2    Khanwalkar, H.3    Manohar, S.M.4    Joshi, K.S.5
  • 7
    • 84891490998 scopus 로고    scopus 로고
    • Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9
    • 23949878
    • Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol 2013, 34(6):3279-3292. 10.1007/s13277-013-1033-3, 23949878.
    • (2013) Tumour Biol , vol.34 , Issue.6 , pp. 3279-3292
    • Ballehaninna, U.K.1    Chamberlain, R.S.2
  • 8
    • 84894277045 scopus 로고    scopus 로고
    • Analytical metabolomics-based approaches to pancreatic cancer
    • Di Gangi I, Vrovsek U, Pazienza V, Mattivi F. Analytical metabolomics-based approaches to pancreatic cancer. Trends Anal Chem 2014, 55:94-116. 10.1016/j.trac.2013.12.006.
    • (2014) Trends Anal Chem , vol.55 , pp. 94-116
    • Di Gangi, I.1    Vrovsek, U.2    Pazienza, V.3    Mattivi, F.4
  • 9
    • 33947430594 scopus 로고    scopus 로고
    • The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
    • 17345146
    • Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007, 26(1):85-110. 10.1007/s10555-007-9044-4, 17345146.
    • (2007) Cancer Metastasis Rev , vol.26 , Issue.1 , pp. 85-110
    • Zhang, J.1    Visser, F.2    King, K.M.3    Baldwin, S.A.4    Young, J.D.5    Cass, C.E.6
  • 10
    • 46649083576 scopus 로고    scopus 로고
    • Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer
    • 18589402
    • Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008, 76(3):322-329. 10.1016/j.bcp.2008.05.011, 18589402.
    • (2008) Biochem Pharmacol , vol.76 , Issue.3 , pp. 322-329
    • Pérez-Torras, S.1    García-Manteiga, J.2    Mercadé, E.3    Casado, F.J.4    Carbó, N.5    Pastor-Anglada, M.6    Mazo, A.7
  • 11
    • 80054749399 scopus 로고    scopus 로고
    • Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1
    • 21965724
    • Wang H, Word BR, Lyn-Cook BD. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1. Anticancer Res 2011, 31(10):3171-3180. 21965724.
    • (2011) Anticancer Res , vol.31 , Issue.10 , pp. 3171-3180
    • Wang, H.1    Word, B.R.2    Lyn-Cook, B.D.3
  • 12
    • 84876481679 scopus 로고    scopus 로고
    • Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
    • 23492684
    • Eto K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kawahata S, Takasawa A, Fukuoka M, Matsuno Y, Asaka M, Sakamoto N. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br J Cancer 2013, 108(7):1488-1494. 10.1038/bjc.2013.108, 23492684.
    • (2013) Br J Cancer , vol.108 , Issue.7 , pp. 1488-1494
    • Eto, K.1    Kawakami, H.2    Kuwatani, M.3    Kudo, T.4    Abe, Y.5    Kawahata, S.6    Takasawa, A.7    Fukuoka, M.8    Matsuno, Y.9    Asaka, M.10    Sakamoto, N.11
  • 16
  • 17
    • 0030598150 scopus 로고    scopus 로고
    • The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines
    • 8947528
    • Miller DW, Fontain M, Kolar C, Lawson T. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 1996, 107(2):301-306. 10.1016/0304-3835(96)04384-4, 8947528.
    • (1996) Cancer Lett , vol.107 , Issue.2 , pp. 301-306
    • Miller, D.W.1    Fontain, M.2    Kolar, C.3    Lawson, T.4
  • 18
    • 58049203872 scopus 로고    scopus 로고
    • C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene
    • 18940792
    • Su N, Kilberg MS. C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene. J Biol Chem 2008, 283(50):35106-35117. 10.1074/jbc.M806874200, 18940792.
    • (2008) J Biol Chem , vol.283 , Issue.50 , pp. 35106-35117
    • Su, N.1    Kilberg, M.S.2
  • 19
    • 77949355546 scopus 로고    scopus 로고
    • High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia?
    • 20164121
    • Pandolfi A, Di Pietro N. High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia?. Cardiovasc Res 2010, 86(1):9-11. 10.1093/cvr/cvq055, 20164121.
    • (2010) Cardiovasc Res , vol.86 , Issue.1 , pp. 9-11
    • Pandolfi, A.1    Di Pietro, N.2
  • 22
    • 0002965760 scopus 로고
    • Generalized Regression Tree
    • Ciampi A. Generalized Regression Tree. Comput Stat Data Anal 1991, 12(1):57-78. 10.1016/0167-9473(91)90103-9.
    • (1991) Comput Stat Data Anal , vol.12 , Issue.1 , pp. 57-78
    • Ciampi, A.1
  • 24
    • 77956868652 scopus 로고    scopus 로고
    • Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells
    • 20824050
    • Hagmann W, Jesnowski R, Löhr JM. Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells. Neoplasia 2010, 12:740-747. 20824050.
    • (2010) Neoplasia , vol.12 , pp. 740-747
    • Hagmann, W.1    Jesnowski, R.2    Löhr, J.M.3
  • 25
    • 79951726466 scopus 로고    scopus 로고
    • Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd)
    • 21205085
    • Nishio R, Tsuchiya H, Yasui T, Matsuura S, Kanki K, Kurimasa A, Hisatome I, Shiota G. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Sci 2011, 102:622-629. 10.1111/j.1349-7006.2010.01837.x, 21205085.
    • (2011) Cancer Sci , vol.102 , pp. 622-629
    • Nishio, R.1    Tsuchiya, H.2    Yasui, T.3    Matsuura, S.4    Kanki, K.5    Kurimasa, A.6    Hisatome, I.7    Shiota, G.8
  • 26
    • 6044267987 scopus 로고    scopus 로고
    • The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma
    • 15501974
    • Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. Clin Cancer Res 2004, 10(20):6956-6961. 10.1158/1078-0432.CCR-04-0224, 15501974.
    • (2004) Clin Cancer Res , vol.10 , Issue.20 , pp. 6956-6961
    • Spratlin, J.1    Sangha, R.2    Glubrecht, D.3    Dabbagh, L.4    Young, J.D.5    Dumontet, C.6    Cass, C.7    Lai, R.8    Mackey, J.R.9
  • 27
    • 84875222769 scopus 로고    scopus 로고
    • Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection
    • 23253379
    • Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013, 153(4):565-575. 10.1016/j.surg.2012.10.010, 23253379.
    • (2013) Surgery , vol.153 , Issue.4 , pp. 565-575
    • Nakagawa, N.1    Murakami, Y.2    Uemura, K.3    Sudo, T.4    Hashimoto, Y.5    Kondo, N.6    Sueda, T.7
  • 29
    • 0034009904 scopus 로고    scopus 로고
    • Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas
    • 10797334
    • Benassai G1, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, Mazzeo F. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000, 73(4):212-218. 10.1002/(SICI)1096-9098(200004)73:4<212::AID-JSO5>3.0.CO;2-D, 10797334.
    • (2000) J Surg Oncol , vol.73 , Issue.4 , pp. 212-218
    • Benassai, G.1.1    Mastrorilli, M.2    Quarto, G.3    Cappiello, A.4    Giani, U.5    Forestieri, P.6    Mazzeo, F.7
  • 31
    • 84892623452 scopus 로고    scopus 로고
    • Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas
    • Strasberg SM, Gao F, Sanford D, Linehan DC, Hawkins WG, Fields R, Carpenter DH, Brunt EM, Phillips C. Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2014, 16(2):150-156. 10.1111/hpb.12094.
    • (2014) HPB (Oxford) , vol.16 , Issue.2 , pp. 150-156
    • Strasberg, S.M.1    Gao, F.2    Sanford, D.3    Linehan, D.C.4    Hawkins, W.G.5    Fields, R.6    Carpenter, D.H.7    Brunt, E.M.8    Phillips, C.9
  • 32
    • 0026130779 scopus 로고
    • Serum CEA and CA 19-9 value in patients with pancreatic cancer or pancreatitis
    • Changchien CS, Yung CY, Tzen KY. Serum CEA and CA 19-9 value in patients with pancreatic cancer or pancreatitis. Changgeng Yi Xue Za Zhi 1991, 14(1):32-38.
    • (1991) Changgeng Yi Xue Za Zhi , vol.14 , Issue.1 , pp. 32-38
    • Changchien, C.S.1    Yung, C.Y.2    Tzen, K.Y.3
  • 33
    • 0028267303 scopus 로고
    • Haglund The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer
    • 7510116
    • Lundin J1, Roberts PJ, Kuusela P, Haglund C, Haglund. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69(3):515-519. 10.1038/bjc.1994.93, 7510116.
    • (1994) Br J Cancer , vol.69 , Issue.3 , pp. 515-519
    • Lundin, J.1    Roberts, P.J.2    Kuusela, P.3    Haglund, C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.